Genotype-to-Phenotype Translation

Genotype-to-phenotype translation is the step that turns raw pharmacogenetic test results into a clinically interpretable statement about how a patient is predicted to handle a drug. A genotype made of star alleles is first resolved into a diplotype, then mapped to a predicted phenotype such as poor, intermediate, normal, or ultrarapid metabolizer.

Definition

Genotype-to-phenotype translation is the process of assigning a predicted functional phenotype, such as a metabolizer status, to a patient based on their inferred diplotype of functional, reduced-function, and non-functional alleles, often via an activity score that aggregates the predicted function of each allele.

Scope

The entry covers the logic of converting allele and diplotype information into predicted phenotype categories, the role of activity scores in making that mapping explicit, and the standardized terminology used to report results. It is a methodological topic about interpretation, not a catalogue of drug-gene dosing rules.

Core questions

• How are individual star alleles assigned a functional status?
• How is a diplotype combined into a single predicted phenotype?
• What does an activity score represent and where does it break down?
• How can result terms be standardized so that laboratories report phenotype consistently?

Key concepts

• Star allele nomenclature
• Diplotype
• Functional, reduced-function, and non-functional alleles
• Predicted metabolizer phenotype
• Activity score
• Standardized result terminology

Key theories

Activity score model

Each allele is assigned a numeric value reflecting its predicted enzyme activity; summing the two alleles' values yields a score that is mapped to a phenotype category, making the genotype-to-phenotype step explicit and reproducible.

Mechanisms

Translation proceeds in stages. Genotyping identifies variants that are organized into star alleles by allele-definition resources such as PharmVar; each allele is annotated with a functional status. The patient's two alleles form a diplotype, and the predicted functions are combined, frequently through an activity score that adds the per-allele values into a total. That total is then mapped onto a phenotype category. Because laboratories historically used different category labels, consensus terminology has been developed so that the same diplotype yields the same reported phenotype across settings, and curated knowledge bases provide the evidence linking alleles to function.

Clinical relevance

Reliable phenotype assignment underlies how pharmacogenomic results are interpreted and acted upon in research and care, and inconsistent translation can make the same genotype appear to mean different things. This entry describes the interpretive method and standardized terminology; it does not specify drug-specific actions or individual treatment decisions.

Epidemiology

Allele frequencies differ substantially across populations, so the relative prevalence of predicted phenotype categories varies by ancestry; allele-definition and frequency resources document this variation.

Evidence & guidelines

Standardized translation rests on allele-definition resources such as PharmVar, consensus result terminology from the Clinical Pharmacogenetics Implementation Consortium, and frameworks for grading the strength of the underlying pharmacogenomic knowledge.

History

Star allele nomenclature emerged from cytochrome P450 genetics, and the 2008 CYP2D6 activity score gave the field a transparent way to collapse diplotypes into phenotype categories. Subsequent consensus efforts standardized the result terms, and allele-definition stewardship moved to dedicated consortia, with knowledge-grading frameworks added to indicate how well-supported each translation is.

Debates

How should phenotype categories be bounded?

Activity-score cutoffs that separate intermediate from normal metabolizers, and the handling of alleles with uncertain function, affect which phenotype a diplotype receives; harmonizing these boundaries across genes and laboratories remains an active standardization effort.

Key figures

• Andrea Gaedigk
• J. Steven Leeder
• Kelly Caudle
• Teri Klein
• Magnus Ingelman-Sundberg

Seminal works

• gaedigk2008
• caudle2017

Frequently asked questions

What is an activity score?

It is a number formed by adding values assigned to each of a patient's two alleles according to their predicted enzyme function; the total is then mapped to a phenotype category such as intermediate or normal metabolizer.

Why standardize phenotype terms?

Because the same diplotype could otherwise be reported with different labels by different laboratories, standardized consensus terms make pharmacogenomic results comparable and interpretable across settings.